Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CPIX's Cash to Debt is ranked higher than
95% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.03 vs. CPIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CPIX' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: No Debt

Equity to Asset 0.86
CPIX's Equity to Asset is ranked higher than
92% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.43 vs. CPIX: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
CPIX' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.91
Current: 0.86

0.42
0.91
Interest Coverage 53.12
CPIX's Interest Coverage is ranked higher than
72% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 53.12 )
Ranked among companies with meaningful Interest Coverage only.
CPIX' s 10-Year Interest Coverage Range
Min: 3.08   Max: 122.47
Current: 53.12

3.08
122.47
F-Score: 8
Z-Score: 6.96
M-Score: -2.72
WACC vs ROIC
14.49%
7.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.41
CPIX's Operating margin (%) is ranked higher than
62% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. CPIX: 8.41 )
Ranked among companies with meaningful Operating margin (%) only.
CPIX' s 10-Year Operating margin (%) Range
Min: -11.87   Max: 23.96
Current: 8.41

-11.87
23.96
Net-margin (%) 5.82
CPIX's Net-margin (%) is ranked higher than
61% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. CPIX: 5.82 )
Ranked among companies with meaningful Net-margin (%) only.
CPIX' s 10-Year Net-margin (%) Range
Min: -6.57   Max: 24.72
Current: 5.82

-6.57
24.72
ROE (%) 2.72
CPIX's ROE (%) is ranked higher than
51% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.48 vs. CPIX: 2.72 )
Ranked among companies with meaningful ROE (%) only.
CPIX' s 10-Year ROE (%) Range
Min: -2.55   Max: 50.74
Current: 2.72

-2.55
50.74
ROA (%) 2.34
CPIX's ROA (%) is ranked higher than
56% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. CPIX: 2.34 )
Ranked among companies with meaningful ROA (%) only.
CPIX' s 10-Year ROA (%) Range
Min: -2.26   Max: 24.03
Current: 2.34

-2.26
24.03
ROC (Joel Greenblatt) (%) 69.65
CPIX's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. CPIX: 69.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46.2   Max: 1632.74
Current: 69.65

-46.2
1632.74
Revenue Growth (3Y)(%) -6.10
CPIX's Revenue Growth (3Y)(%) is ranked lower than
52% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.40 vs. CPIX: -6.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CPIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.1   Max: 47.5
Current: -6.1

-7.1
47.5
EBITDA Growth (3Y)(%) -16.00
CPIX's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -31.90 vs. CPIX: -16.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CPIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16   Max: 102.7
Current: -16

-16
102.7
EPS Growth (3Y)(%) -20.60
CPIX's EPS Growth (3Y)(%) is ranked higher than
59% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -53.60 vs. CPIX: -20.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CPIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.6   Max: 34.2
Current: -20.6

-20.6
34.2
» CPIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CPIX Guru Trades in Q2 2014

John Rogers 2,663,170 sh (-0.01%)
Jim Simons 76,800 sh (-19.66%)
» More
Q3 2014

CPIX Guru Trades in Q3 2014

Jim Simons 84,100 sh (+9.51%)
John Rogers 2,607,251 sh (-2.10%)
» More
Q4 2014

CPIX Guru Trades in Q4 2014

Jim Simons 120,900 sh (+43.76%)
John Rogers 2,085,426 sh (unchged)
John Rogers 2,085,426 sh (unchged)
John Rogers 2,085,426 sh (unchged)
John Rogers 2,085,426 sh (-20.01%)
» More
Q1 2015

CPIX Guru Trades in Q1 2015

Chuck Royce 11,700 sh (New)
Jim Simons 170,188 sh (+40.77%)
John Rogers 1,907,242 sh (-8.54%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 56.50
CPIX's P/E(ttm) is ranked higher than
56% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 83.70 vs. CPIX: 56.50 )
Ranked among companies with meaningful P/E(ttm) only.
CPIX' s 10-Year P/E(ttm) Range
Min: 12.4   Max: 302.94
Current: 56.5

12.4
302.94
Forward P/E 50.00
CPIX's Forward P/E is ranked higher than
55% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 129.87 vs. CPIX: 50.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 55.90
CPIX's PE(NRI) is ranked higher than
63% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 169.30 vs. CPIX: 55.90 )
Ranked among companies with meaningful PE(NRI) only.
CPIX' s 10-Year PE(NRI) Range
Min: 12.55   Max: 257.5
Current: 55.9

12.55
257.5
P/B 1.50
CPIX's P/B is ranked higher than
80% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. CPIX: 1.50 )
Ranked among companies with meaningful P/B only.
CPIX' s 10-Year P/B Range
Min: 0.9   Max: 4.84
Current: 1.5

0.9
4.84
P/S 3.23
CPIX's P/S is ranked higher than
51% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 3.23 )
Ranked among companies with meaningful P/S only.
CPIX' s 10-Year P/S Range
Min: 1.65   Max: 6.82
Current: 3.23

1.65
6.82
PFCF 45.30
CPIX's PFCF is ranked higher than
71% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 491.77 vs. CPIX: 45.30 )
Ranked among companies with meaningful PFCF only.
CPIX' s 10-Year PFCF Range
Min: 12.69   Max: 1432
Current: 45.3

12.69
1432
POCF 15.29
CPIX's POCF is ranked higher than
84% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.87 vs. CPIX: 15.29 )
Ranked among companies with meaningful POCF only.
CPIX' s 10-Year POCF Range
Min: 11.33   Max: 769
Current: 15.29

11.33
769
EV-to-EBIT 19.92
CPIX's EV-to-EBIT is ranked higher than
77% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 139.28 vs. CPIX: 19.92 )
Ranked among companies with meaningful EV-to-EBIT only.
CPIX' s 10-Year EV-to-EBIT Range
Min: -16.4   Max: 265.4
Current: 19.92

-16.4
265.4
Shiller P/E 46.30
CPIX's Shiller P/E is ranked higher than
69% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 46.30 )
Ranked among companies with meaningful Shiller P/E only.
CPIX' s 10-Year Shiller P/E Range
Min: 16.26   Max: 46.67
Current: 46.3

16.26
46.67
Current Ratio 5.68
CPIX's Current Ratio is ranked higher than
87% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. CPIX: 5.68 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s 10-Year Current Ratio Range
Min: 1.45   Max: 14.46
Current: 5.68

1.45
14.46
Quick Ratio 5.29
CPIX's Quick Ratio is ranked higher than
87% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. CPIX: 5.29 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s 10-Year Quick Ratio Range
Min: 1.38   Max: 13.46
Current: 5.29

1.38
13.46
Days Inventory 435.34
CPIX's Days Inventory is ranked lower than
71% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 151.00 vs. CPIX: 435.34 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s 10-Year Days Inventory Range
Min: 92.58   Max: 636.33
Current: 435.34

92.58
636.33
Days Sales Outstanding 50.38
CPIX's Days Sales Outstanding is ranked higher than
78% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.78 vs. CPIX: 50.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s 10-Year Days Sales Outstanding Range
Min: 30.88   Max: 104.9
Current: 50.38

30.88
104.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.90
CPIX's Price/Net Cash is ranked higher than
96% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 2.90 )
Ranked among companies with meaningful Price/Net Cash only.
CPIX' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 6.72
Current: 2.9

1.37
6.72
Price/Net Current Asset Value 2.50
CPIX's Price/Net Current Asset Value is ranked higher than
97% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 2.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPIX' s 10-Year Price/Net Current Asset Value Range
Min: 1.07   Max: 5.38
Current: 2.5

1.07
5.38
Price/Tangible Book 2.00
CPIX's Price/Tangible Book is ranked higher than
80% of the 824 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.50 vs. CPIX: 2.00 )
Ranked among companies with meaningful Price/Tangible Book only.
CPIX' s 10-Year Price/Tangible Book Range
Min: 1.04   Max: 5.21
Current: 2

1.04
5.21
Price/DCF (Projected) 1.50
CPIX's Price/DCF (Projected) is ranked higher than
87% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. CPIX: 1.50 )
Ranked among companies with meaningful Price/DCF (Projected) only.
CPIX' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 1.45
Current: 1.5

0.7
1.45
Price/Median PS Value 1.20
CPIX's Price/Median PS Value is ranked higher than
69% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. CPIX: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
CPIX' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 2.5
Current: 1.2

0.65
2.5
Price/Graham Number 2.20
CPIX's Price/Graham Number is ranked higher than
77% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 2.20 )
Ranked among companies with meaningful Price/Graham Number only.
CPIX' s 10-Year Price/Graham Number Range
Min: 0.8   Max: 5.04
Current: 2.2

0.8
5.04
Earnings Yield (Greenblatt) 4.90
CPIX's Earnings Yield (Greenblatt) is ranked higher than
74% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. CPIX: 4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CPIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 76.6
Current: 4.9

0.4
76.6
Forward Rate of Return (Yacktman) -0.18
CPIX's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: -0.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
CPIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.5   Max: 17.4
Current: -0.18

0.5
17.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CBJ.Germany,
Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which they do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
CUMBERLAND PHARMACEUTICALS INC Financials May 22 2015
10-Q for Cumberland Pharmaceuticals, Inc. May 17 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 15 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition May 08 2015
10-K for Cumberland Pharmaceuticals, Inc. May 07 2015
Cumberland posts 1Q profit May 07 2015
Cumberland posts 1Q profit May 07 2015
Cumberland Pharmaceuticals Reports First Quarter 2015 Financial Results May 07 2015
Cumberland Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today May 07 2015
Cumberland Pharmaceuticals Reports First Quarter 2015 Financial Results May 07 2015
Q1 2015 Cumberland Pharmaceuticals Inc Earnings Release - After Market Close May 07 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... May 01 2015
Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results Apr 30 2015
Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results Apr 30 2015
Message From CEO Mar 13 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 09 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 04 2015
Cumberland posts 4Q profit Mar 03 2015
Cumberland posts 4Q profit Mar 03 2015
Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones Mar 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK